EXPLORER-HCM - new possibilities in the treatment of outflow tract obstruction in hypertrophic cardiomyopathy
2021
Abstract
Phase 3, multicentre, randomized, double-blind, placebo-controlled EXPLORER-HCM trial evaluated mavacamten, a cardiac myosin inhibitor, in symptomatic patients with hypertrophic cardiomyopathy and outflow tract obstruction. In total, 251 patients were enrolled and randomly assigned to mavacamten (n = 123) or placebo (n = 128) and treated for 30 weeks.
The treatment with mavacamten improved exercise capacity, left ventricular outflow tract obstruction, NYHA functional class, and subjectively assessed health status in these patients.